The macamide N-3-methoxybenzyl-linoleamide is a time-dependent fatty acid amide hydrolase (FAAH) inhibitor

Molecular Neurobiology

Volumn 48, Issue 2, 2013, Pages 333-339

  Almukadi, Haifa ^a   Wu, Hui ^a   Böhlke, Mark ^a   Kelley, Charles J ^a   Maher, Timothy J ^a   Pino Figueroa, Alejandro ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Fatty acid amide hydrolase inhibitor; Maca; Macamide N 3 methoxybenzyl linoleamide

Indexed keywords

ACYLGLYCEROL LIPASE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; FATTY ACID AMIDASE INHIBITOR; N 3 METHOXYBENZYL LINOLEAMIDE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME DEGRADATION; ENZYME INACTIVATION; IN VITRO STUDY; LEPIDIUM; LEPIDIUM MEYENII; NONHUMAN; PLANT ROOT;

AMIDOHYDROLASES; ENZYME ASSAYS; ENZYME INHIBITORS; HUMANS; KINETICS; LINOLEIC ACIDS; MONOACYLGLYCEROL LIPASES; TIME FACTORS;

EID: 84885305898     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8499-2     Document Type: Conference Paper

References (42)

1. Pino-Figueroa A (2009) In vivo and in vitro neuroprotective effects of the pentane soluble compounds from Lepidium meyenii (Maca). Dissertation, Massachusetts College of Pharmacy and Health Sciences University
2. Pino-Figueroa A, Nguyen D, Maher TJ (2010) Neuroprotective effects of Lepidium meyenii (Maca). Ann N Y Acad Sci 1199:77-85
3. Pino-Figueroa A, Vu H, Kelley CJ, Maher TJ (2011) Mechanism of action of Lepidium meyenii (Maca): an explanation for its neuroprotective activity. Am J Neuroprotec Neuroregen 3:87-92
4. Wu H (2011) Macamides and their synthetic analogs as potential FAAH inhibitors. Dissertation, Massachusetts College of Pharmacy and Health Sciences University
5. Vu H., (2012) Fatty acid amide hydrolase (FAAH) inhibitors: discovery in Lepidium meyenii (Maca) extracts. In: Conference Proceedings of The National Conference On Undergraduate Research (NCUR), Weber State University, Utah, 29-31 March 2012, 410-417
6. Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci STKE 2002:1-6
7. Kumar RN, Chambers WA, Pertwee RG (2001) Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 56:1059-1068
8. Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147(Suppl 1):S163-S171
9. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z (1998) Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 71:1525-1534
10. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066
11. Day TA, Rakhshan F, Deutsch DG, Barker EL (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59:1369-1375
12. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R (2011) Endocannabinoids and traumatic brain injury. Br J Pharmacol 163:1402-1410
13. van der Stelt M, Di Marzo V (2005) Cannabinoid receptors and their role in neuroprotection. Neuromol Med 7:37-50
14. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A (2010) Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 224:37-47
15. Pacher P, Bátkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462
16. Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA (2010) Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci 86:615-623
17. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611
18. van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bär PR, Veldink GA, Vliegenthart JFG, Di Marzo V, Nicolay K (2001) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21:8765-8771
19. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N (2003) Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23:7767-7775
20. Schomacher M, Muller HD, Sommer C, Schwab S, Schabitz WR (2008) Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res 1240:213-220
21. Shouman B, Fontaine RH, Baud O, Schwendimann L, Keller M, Spedding M, Lelièvre V, Gressens P (2006) Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br J Pharmacol 148:442-451
22. Gallily R, Breuer A, Mechoulam R (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406:R5-R7
23. Cravatt BF, Lichtman AH (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475
24. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stiff C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF (2011) Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 338:114-124
25. Gonzales GF, Gonzales C, Gonzales-Castaneda C (2009) Lepidium meyenii (Maca): a plant from the highlands of Peru-from tradition to science. Forsch Komplementmed 16:373-380
26. Muhammad I, Zhao J, Dunbar DC, Khan IA (2002) Constituents of Lepidium meyenii 'Maca'. Phytochem 59:105-110
27. Zhao J, Muhammad I, Dunbar DC, Mustafa J, Khan IA (2005) New alkamides from Maca (Lepidium meyenii). J Agric Food Chem 53:690-693
28. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, Cravatt BF (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46:13019-13030
29. Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimarães CRW, Jorgensen WL, Cravatt BF (2005) Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48:1849-1856
30. Muccioli GG, Labar G, Lambert DM (2008) CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. ChemBioChem 9:2704-2710
31. Tian G, Paschetto KA, Gharahdaghi F, Gordon E, Wilkins DE, Luo X, Scott CW (2011) Mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles: long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency. Biochemistry 50:6867-6878
32. Scott CW, Tian G, Yu XH, Paschetto KA, Wilkins DE, Meury L, Cao CQ, Varnes J, Edwards PD (2011) Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase. Eur J Pharmacol 667:74-79
33. Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, Keita AS, Stepniewska K, Traore K, Diakite SA, Ndiaye D, Sa JM, Anderson JM, Fay MP, Long CA, Diakite M, Fairhurst RM (2013) Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis 207(11):1655-1663
34. Ning M, Li L, Li J, Li Z, Li R, Zhou T, Lu W (2012) In vitro screening of reversible and time-dependent inhibition on CYP3A by TM208 and TM209 in rat liver microsomes. Acta Pharm Sin B 2:181-187
35. Kage KL, Richardson PL, Traphagen L, Severin J, Pereda-Lopez A, Lubben T, Davis-Taber R, Vos MH, Bartley D, Walter K, Harlan J, Solomon L, Warrior U, Holzman TF, Faltynek C, Surowy CS, Scott VE (2007) A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase. J Neurosci Methods 161:47-54
36. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci U S A 97:5044-5049
37. Silverman R (2002) The organic chemistry of enzyme-catalyzed reactions. Elsevier, Oxford
38. Voet D, Voet J, Pratt C (2008) Chapter 12. Enzyme kinetics, inhibition, and regulation. In: Principles of biochemistry, Wiley, New York
39. McCollom MM, Villinski JR, McPhail KL, Craker LE, Gafner S (2005) Analysis of macamides in samples of Maca (Lepidium meyenii) by HPLC-UV-MS/MS. Phytochem Anal 16:463-469
40. Petrosino S, Di Marzo V (2010) FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11:51-62
41. Lewis RA, Robin JL (1985) Arachidonic acid derivatives as mediators of asthma. J Allergy Clin Immunol 76:259-264
42. Cunningham FM, Woollard PM, Camp RD (1985) Proinflammatory properties of unsaturated fatty acids and their monohydroxy metabolites. Prostaglandins 30:497-509